CVS Health Corp vs Uber Technologies Inc — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Uber Technologies Inc trades at $70.17 (market cap $139.81B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Uber Technologies Inc for 88 Days on average.
| CVS | UBER | |
|---|---|---|
Market Cap | $112.49B | $139.81B |
Volume | 8,467,392 | 11,879,194 |
Sector | Health | Technology |
52-Week High | $110.60 | $99.72 |
52-Week Low | $70.08 | $65.94 |
Typical Hold Time | 83 Days | 88 Days |
Enterprise Value | $174.83B | $149.15B |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Uber (UBER) trades at $70.24, up 1.68% on the day, with a bearish technical signal from moving averages but strong fundamentals including 2025 revenue of $52.02 billion and net income of $10.05 billion. The company has beaten EPS estimates in two of the last three quarters and expanded its Uber Eats partnership with Costco to 47 states as of September 16, 2026. Operating cash flow grew to $10.10 billion in 2025, supporting a robust balance sheet with $6.98 billion in cash.
The outlook is positive given analyst consensus of a $104.72 price target and 82.54% buy ratings, though risks include a projected negative net cash flow in 2026 and competitive pressures from autonomous vehicle entrants. Upside is driven by earnings momentum and strategic expansions, while investor caution is warranted on execution and capital expenditure trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →